Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861083 | 0.79 | KDM4E (0.60) | KDM4EDPP4SLC6A4MEN1KMT2A | |
| SCHEMBL2868996 | 0.77 | KDM4E (0.58) | KDM4EDPP4SLC6A4MEN1KMT2A | |
| SCHEMBL2860296 | 0.76 | KDM4E (0.56) | KDM4EDPP4SLC6A4MEN1KMT2A | |
| SCHEMBL1738419 | 0.75 | NPC1 (0.74) | KDM4ENPC1RAB9AMAPTPKM | |
| SCHEMBL31631301 | 0.75 | NPC1 (0.74) | KDM4ENPC1RAB9AMAPTPKM | |
| SCHEMBL13067048 | 0.75 | KDM4E (0.70) | KDM4EDPP4SLC6A4MEN1KMT2A | |
| SCHEMBL6357432 | 0.73 | BDKRB1 (0.58) | NPC1RAB9AMAPTPKMDPP4 | |
| SCHEMBL2867705 | 0.73 | KDM4E (0.56) | KDM4EDPP4SLC6A4MEN1KMT2A | |
| SCHEMBL3277211 | 0.72 | LTA4H (0.50) | NPC1MAPTPKMCYP1A2CYP2C19 | |
| SCHEMBL13067056 | 0.72 | HTT (0.55) | KDM4ESLC6A4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| CN-101704810-A | Cycloalkyl inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO | 2010-05-12 | — | — | CN | disclosed |
| CN-100558697-C | Cycloalkyl inhibitors of potassium channel function | SQUIBB BRISTOL MYERS CO ICAGEN (US) | 2009-11-11 | — | — | CN | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| CN-1732146-A | Cycloalkyl inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2006-02-08 | — | — | CN | disclosed |
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | LLOYD JOHN | 2005-10-20 | — | — | US | disclosed |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | ICAGEN, INC. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234106-A1 | Cycloalkyl inhibitors of potassium channel function | KCNJ2, KCNN3, KCNQ5 | KDM4E 820/4885NPC1 675/4885RAB9A 2415/4885 |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | KDM4E 820/4885NPC1 675/4885RAB9A 2415/4885 |
| US-20040072880-A1 | Cycloalkyl inhibitors of potassium channel function | KCNN1, KCNN2, KCNH2 | KDM4E 1323/4885NPC1 587/4885RAB9A 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.